Minerva Neurosciences, Inc. (NASDAQ:NERV – Free Report) – Equities research analysts at HC Wainwright lowered their Q2 2024 EPS estimates for shares of Minerva Neurosciences in a research report issued to clients and investors on Thursday, May 2nd. HC Wainwright analyst D. Tsao now expects that the biopharmaceutical company will post earnings of ($0.97) per share for the quarter, down from their prior estimate of ($0.77). HC Wainwright has a “Neutral” rating and a $7.00 price target on the stock. The consensus estimate for Minerva Neurosciences’ current full-year earnings is ($1.89) per share. HC Wainwright also issued estimates for Minerva Neurosciences’ Q3 2024 earnings at ($0.73) EPS, Q4 2024 earnings at $0.95 EPS, FY2024 earnings at ($1.89) EPS, FY2025 earnings at ($3.60) EPS, FY2026 earnings at ($4.36) EPS, FY2027 earnings at ($1.05) EPS and FY2028 earnings at $0.66 EPS.
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings data on Wednesday, May 1st. The biopharmaceutical company reported ($1.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.07.
Check Out Our Latest Stock Report on NERV
Minerva Neurosciences Stock Up 0.9 %
Shares of NERV opened at $2.37 on Monday. Minerva Neurosciences has a twelve month low of $2.29 and a twelve month high of $13.49. The stock has a market cap of $16.57 million, a PE ratio of -0.53 and a beta of 0.27. The business’s 50-day moving average price is $2.66 and its 200-day moving average price is $5.30.
About Minerva Neurosciences
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
Further Reading
- Five stocks we like better than Minerva Neurosciences
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 4/29 – 5/3
- What is a Secondary Public Offering? What Investors Need to Know
- Apple’s Earnings Show Investors Its Strength and Its Weakness
- Energy and Oil Stocks Explained
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.